Lilly and Boehringer Ingelheim Launch Biosimilar Lantus In UK, Germany
This article was originally published in The Pink Sheet Daily
Executive Summary
The cost of biosimilar Lantus to payers is at around a 15% discount to the originator product in the UK, but cost-savings are expected to vary across Europe as supply contracts with health insurers and hospitals are negotiated.